Tianjin Lisheng Pharmaceutical Co.,Ltd.
Simbolis: 002393.SZ
SHZ
25.45
CNYRinkos kaina šiandien
12.3975
P/E santykis
7.8104
PEG koeficientas
4.64B
MRK kapitalizacija
- 0.01%
DIV pajamingumas
Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393-SZ) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 8384.27 | 2220.2 | 1993.6 | 1651.9 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 371.13 | 231.3 | 200.3 | -31.9 | ||||||||||||||||||
balance-sheet.row.net-receivables | 1996.79 | 321.5 | 427.7 | 461.9 | ||||||||||||||||||
balance-sheet.row.inventory | 779.47 | 176.3 | 199.1 | 228.8 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 449.96 | 100.5 | 4.9 | 13.9 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 11610.5 | 2818.5 | 2625.4 | 2356.4 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 4045.76 | 981.9 | 1029.8 | 1136.7 | ||||||||||||||||||
balance-sheet.row.goodwill | 57.92 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 567.45 | 124.9 | 135.5 | 144.2 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 625.37 | 124.9 | 135.5 | 144.2 | ||||||||||||||||||
balance-sheet.row.long-term-investments | 6115.65 | 1810.6 | 1180.6 | 1531.8 | ||||||||||||||||||
balance-sheet.row.tax-assets | 134.98 | 39.5 | 33.7 | 16.3 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 177.12 | 5.3 | 286.1 | 5.5 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 11098.87 | 2962.1 | 2665.6 | 2834.5 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 22709.37 | 5780.6 | 5291 | 5190.9 | ||||||||||||||||||
balance-sheet.row.account-payables | 331.1 | 84.8 | 146.4 | 90.5 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 228.64 | 59.1 | 39.7 | 28.5 | ||||||||||||||||||
balance-sheet.row.tax-payables | 149.6 | 14.6 | 42.5 | 20.3 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 17.77 | 3.9 | 5.4 | 6.2 | ||||||||||||||||||
Deferred Revenue Non Current | 117.89 | 27.9 | 31.8 | 31.7 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 741.36 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 1093.6 | 467.4 | 543.9 | 1.4 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 906.67 | 223 | 211.7 | 228 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 17.77 | 3.9 | 5.4 | 6.2 | ||||||||||||||||||
balance-sheet.row.total-liab | 3750.51 | 849.2 | 941.7 | 780.4 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 736.51 | 184.3 | 184 | 182.5 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 5422.19 | 1393.7 | 1126.6 | 1098 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 9405.31 | 1612 | 1328.7 | 1439.4 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 3334.68 | 1713.4 | 1710.1 | 1690.7 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 18898.68 | 4903.4 | 4349.4 | 4410.5 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 22709.37 | 5780.6 | 5291 | 5190.9 | ||||||||||||||||||
balance-sheet.row.minority-interest | 32.24 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-equity | 18930.92 | 4903.4 | 4349.4 | 4410.5 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 22709.37 | - | - | - | ||||||||||||||||||
Total Investments | 6486.78 | 2041.9 | 1380.9 | 1499.8 | ||||||||||||||||||
balance-sheet.row.total-debt | 246.41 | 63 | 45.1 | 34.7 | ||||||||||||||||||
balance-sheet.row.net-debt | -7705.06 | -1925.9 | -1748.2 | -1617.2 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 374.48 | 361.8 | 93.6 | 122.1 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | -0.02 | 67.3 | 66.1 | 60.2 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | -36.38 | -5.5 | -15.4 | -8.7 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 8.97 | -136.5 | 15.4 | 8.7 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 29.92 | 1.6 | 137.9 | 17.6 | ||||||||||||||||||
cash-flows.row.account-receivables | 17.52 | 17.5 | 25.1 | -19.5 | ||||||||||||||||||
cash-flows.row.inventory | 8.91 | 8.9 | 11.1 | -4.4 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | -28.3 | 117 | 50.2 | ||||||||||||||||||
cash-flows.row.other-working-capital | 3.49 | 3.5 | -15.4 | -8.7 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | -128.58 | -79.3 | 33.8 | -3.6 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 245.52 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -59.66 | -61.7 | -40.9 | -88.2 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 147.74 | 151.5 | 115.3 | 0.1 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | -580 | -470 | -320 | -70 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 339.7 | 390 | 90 | 82 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 31.53 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -120.69 | 9.9 | -155.6 | -76.1 | ||||||||||||||||||
cash-flows.row.debt-repayment | -22.45 | 0 | -0.1 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | -6.29 | -54.7 | -54.7 | -18.2 | ||||||||||||||||||
cash-flows.row.other-financing-activites | -65.85 | 5.9 | 21 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -143.04 | -48.8 | -33.8 | -18.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 30.37 | 25.1 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | -7.46 | 195.7 | 142 | 102 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 7910.84 | 1989 | 1769.6 | 1627.7 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 7918.29 | 1793.3 | 1627.7 | 1525.7 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 245.52 | 209.5 | 331.4 | 196.3 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -59.66 | -61.7 | -40.9 | -88.2 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 185.86 | 147.8 | 290.5 | 108.1 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1170.61 | 1130.2 | 1146.6 | 1091.9 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 515.47 | 495.6 | 486.3 | 454.5 | ||||||||||||||||||
income-statement-row.row.gross-profit | 655.14 | 634.5 | 660.3 | 637.5 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 103.47 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 24.94 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 314.2 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | -29.02 | -13.8 | 108.4 | 96.1 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 564.73 | 521.9 | 576.8 | 591.8 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 1080.2 | 1017.5 | 1063.1 | 1046.3 | ||||||||||||||||||
income-statement-row.row.interest-income | -29.87 | 61.2 | 68.3 | 87.6 | ||||||||||||||||||
income-statement-row.row.interest-expense | 1.54 | 0.9 | 0.9 | 0.3 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 314.2 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 49.9 | 296.6 | -57.3 | 0.2 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | -29.02 | -13.8 | 108.4 | 96.1 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 49.9 | 296.6 | -57.3 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 1.54 | 0.9 | 0.9 | 0.3 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | -194.14 | 67.3 | 66.1 | 75.8 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | 175.88 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | 370.02 | 112.6 | 175.7 | 136.9 | ||||||||||||||||||
income-statement-row.row.income-before-tax | 419.92 | 409.2 | 118.4 | 137.1 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 57.56 | 58.4 | 24.8 | 15 | ||||||||||||||||||
income-statement-row.row.net-income | 374.48 | 361.8 | 93.6 | 122.1 |
Dažnai užduodami klausimai
Kas yra Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ) bendras turtas?
Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ) bendras turtas yra 5780604152.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 594641936.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.560.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 1.019.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.320.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.316.
Kas yra Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 361827990.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 63035414.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 521915434.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 1952585069.000.